医护人员对接种猴痘疫苗的接受度：系统评价和荟萃分析。

INTRODUCTION: Mpox is a zoonotic viral disease that emerged in May 2022 and has since shown a high prevalence in non-mpox-endemic areas, resulting in an outbreak that caused more than 84,000 cases in 110 countries around the globe. Several vaccines are available to prevent the disease, and multiple studies have been conducted to assess the attitudes of different populations toward receiving the mpox vaccine. This study systematically reviews all the studies conducted on mpox vaccine acceptance/hesitancy among healthcare workers. METHODS: A systematic literature search was conducted through four electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, up to March 2023. Studies that described mpox vaccine acceptance/hesitancy among healthcare workers were included, and the data were extracted using a uniform extraction sheet. Following the extraction, the meta-analysis included ten studies with 7322 healthcare workers. Three researchers independently assessed the risk of bias in the included study using the Newcastle-Ottawa Scale (NOS). RESULTS: Ten studies were included in the review. This review indicates that the prevalence of mpox vaccine acceptance was 58.5%, and the prevalence of mpox vaccine hesitancy was 41.5%. There was a higher prevalence of acceptance in countries located in Asian and African areas compared to those in North America and Europe, estimated at 68% and 44.3%, respectively. Among the studies conducted solely among physicians, there was a high prevalence of mpox vaccine acceptance, at 77.1%, compared to 49% in studies that included all healthcare workers. CONCLUSION: There is a significant variation in the prevalence of mpox vaccine acceptance among different populations. Further research is needed to identify the factors that contribute to this variation and to develop interventions to increase vaccine acceptance. In addition, it is important to promote research on mpox vaccine acceptance and hesitancy among healthcare workers in countries where data is limited. This research will help policymakers develop effective policies to increase acceptance and reduce the disease burden.

简介：猴痘是一种人畜共患的病毒性疾病，于 2022 年 5 月出现，此后在非猴痘流行地区的发病率很高，导致全球 110 个国家爆发了超过 84000 例病例。有几种疫苗可用于预防这种疾病，并且已经进行了多项研究来评估不同人群对接种猴痘疫苗的态度。本研究系统地综述了所有关于医护人员对猴痘疫苗接受/犹豫的研究。

方法：通过四个电子数据库（PubMed、Scopus、Web of Science 和 Google Scholar）进行了系统的文献检索，截至 2023 年 3 月。纳入了描述医护人员对猴痘疫苗接受/犹豫的研究，并使用统一的提取表提取数据。提取后，meta 分析包括了十项研究，涉及 7322 名医护人员。三名研究人员使用纽卡斯尔-渥太华量表（NOS）独立评估纳入研究的偏倚风险。

结果：综述纳入了十项研究。本研究表明，猴痘疫苗接受率为 58.5%，猴痘疫苗犹豫率为 41.5%。与北美和欧洲相比，亚洲和非洲地区的国家的接受率更高，分别为 68%和 44.3%。在仅针对医生进行的研究中，猴痘疫苗的接受率较高，为 77.1%，而在包括所有医护人员的研究中，这一比例为 49%。

结论：不同人群的猴痘疫苗接受率存在显著差异。需要进一步研究确定导致这种差异的因素，并制定干预措施以提高疫苗的接受率。此外，重要的是要促进在数据有限的国家进行医护人员对猴痘疫苗接受和犹豫的研究。这项研究将有助于政策制定者制定有效的政策，以提高接受率并减轻疾病负担。